OncoMatch/Clinical Trials/NCT07215949
Zilucoplan for Severe gMG Exacerbations
Is NCT07215949 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Zilucoplan® for generalized myasthenia gravis (gmg).
Treatment: Zilucoplan® — This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IVA, MGFA CLASS IVB (MGFA)
MGFA class II - IVb
Prior therapy
Cannot have received: C5 inhibitor
Current use or known failure of C5 inhibitors in the previous 3 months
Cannot have received: plasma exchange
Exception: initiation in the past 4 weeks
Initiation of plasma exchange ... in the past 4 weeks
Cannot have received: IVIG
Exception: initiation in the past 4 weeks
Initiation of ... IVIG in the past 4 weeks
Cannot have received: anti-CD20 antibody (rituximab)
Rituximab use in the previous 9 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Ohio State University · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07215949 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior C5 inhibitor, plasma exchange, IVIG disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA CLASS II or MGFA CLASS III or MGFA CLASS IVA or MGFA CLASS IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify